|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
|
WO1997009976A2
(en)
|
1995-09-01 |
1997-03-20 |
Washington University |
Method of reducing neurotoxic injury with zinc chelators
|
|
AU719633B2
(en)
|
1996-03-22 |
2000-05-11 |
Du Pont Pharmaceuticals Company |
Novel asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
|
|
DE69807222T2
(de)
|
1997-06-02 |
2003-04-17 |
Janssen Pharmaceutica N.V., Beerse |
(imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
|
|
WO1999004794A1
(en)
|
1997-07-25 |
1999-02-04 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
|
US6525042B1
(en)
|
1997-09-30 |
2003-02-25 |
Daiichi Pharmaceutical Co., Ltd. |
Sulfonyl derivatives
|
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
|
WO1999032100A2
(en)
|
1997-12-19 |
1999-07-01 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
|
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
US6635278B1
(en)
*
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
AP1654A
(en)
|
1999-03-24 |
2006-09-01 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds.
|
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
HUP0302960A3
(en)
|
2000-09-15 |
2007-03-28 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
|
|
DE60137435D1
(de)
|
2000-09-15 |
2009-03-05 |
Anormed Inc |
Chemokin rezeptor bindenden heterozyklische verbindungen
|
|
IL154227A0
(en)
|
2000-09-15 |
2003-07-31 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
|
US6964967B2
(en)
|
2000-12-11 |
2005-11-15 |
Amgen, Inc. |
Substituted pyrido[2,3-d]pyrimidines and methods for their use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
SI1411918T1
(sl)
|
2001-07-31 |
2012-04-30 |
Genzyme Global S A R L |
Postopki za mobilizacijo progenitorskih/matičnih celic
|
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
|
CN100412062C
(zh)
|
2001-09-12 |
2008-08-20 |
阿诺麦德股份有限公司 |
对映体纯的氨基取代稠合双环的合成
|
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
BRPI0215050B8
(pt)
|
2001-12-21 |
2021-05-25 |
Anormed Inc |
compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
|
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
|
DK1536827T3
(da)
|
2002-08-14 |
2009-04-20 |
Silence Therapeutics Ag |
Anvendelse af proteinkinase N-beta
|
|
EP1571146A4
(en)
|
2002-12-10 |
2010-09-01 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
|
|
EP1613613B1
(en)
|
2003-04-11 |
2021-06-02 |
Genzyme Corporation |
Cxcr4 chemokine receptor binding compounds
|
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
|
EP1615633B1
(en)
|
2003-04-22 |
2012-08-15 |
Genzyme Corporation |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
CA2558389C
(en)
|
2004-03-15 |
2013-10-08 |
Anormed, Inc. |
Process for the synthesis of a cxcr4 antagonist
|
|
WO2005100340A2
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
|
WO2006020415A1
(en)
|
2004-08-02 |
2006-02-23 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
CA2577100A1
(en)
|
2004-08-16 |
2006-03-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
JP2008511669A
(ja)
|
2004-09-02 |
2008-04-17 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
US20080171740A1
(en)
|
2004-09-24 |
2008-07-17 |
Smithkline Beecham Corporation |
Chemical Compounds
|
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
US20090093454A1
(en)
|
2005-03-04 |
2009-04-09 |
Kristjan Gudmundsson |
Chemical Compounds
|
|
US20090203533A1
(en)
|
2005-07-08 |
2009-08-13 |
Siemens Medicals Solutions Diagnositcs Gmbh |
Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
|
|
JP2009500451A
(ja)
|
2005-07-11 |
2009-01-08 |
スミスクライン ビーチャム コーポレーション |
ピラノピリジン化合物
|
|
SG139221A1
(en)
|
2005-08-02 |
2008-02-29 |
Ineos Europe Ltd |
Diene polymerisation
|
|
JP2009507795A
(ja)
|
2005-08-31 |
2009-02-26 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
WO2007058322A1
(ja)
|
2005-11-18 |
2007-05-24 |
Ono Pharmaceutical Co., Ltd. |
塩基性基を含有する化合物およびその用途
|
|
JP2009517474A
(ja)
|
2005-11-30 |
2009-04-30 |
シェーリング コーポレイション |
Ccr5拮抗剤およびcxcr4拮抗剤の組み合わせを含む組成物
|
|
AR059197A1
(es)
|
2006-01-25 |
2008-03-19 |
Smithkline Beecham Corp |
Derivados de indazolo piridina para el tratamiento de hiv
|
|
US20100227880A1
(en)
|
2006-01-25 |
2010-09-09 |
Kristjan Gudmundsson |
Chemical compounds
|
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
|
AU2007258907A1
(en)
|
2006-06-12 |
2007-12-21 |
Pfizer Products Inc. |
CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
|
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
|
CN101855222A
(zh)
|
2007-05-10 |
2010-10-06 |
通用电气健康护理有限公司 |
对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
|
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
|
JP5690715B2
(ja)
|
2008-03-28 |
2015-03-25 |
アルテイリス・セラピユーテイクス |
ケモカイン受容体調節因子
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
|
WO2010077613A1
(en)
|
2008-12-09 |
2010-07-08 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
WO2011036270A1
(en)
|
2009-09-28 |
2011-03-31 |
Kerry Group Services International Limited |
Pharmaceutical composition
|
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
|
US20110290821A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
|
WO2012047339A2
(en)
|
2010-06-28 |
2012-04-12 |
The General Hospital Corporation |
Anti-cxcr4 as a sensitizer to cancer therapeutics
|
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
|
WO2012058241A2
(en)
|
2010-10-26 |
2012-05-03 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
|
WO2012075362A2
(en)
|
2010-12-03 |
2012-06-07 |
Emory University |
Chemokine cxcr4 receptor modulators and used related thereto
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CA2821985C
(en)
|
2011-01-11 |
2019-07-09 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
|
KR20200016407A
(ko)
|
2011-05-16 |
2020-02-14 |
젠자임 코포레이션 |
Cxcr4 길항제의 용도
|
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2860995A1
(en)
|
2012-01-12 |
2013-07-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
|
CA2892490A1
(en)
|
2012-11-26 |
2014-05-30 |
Caris Science, Inc. |
Biomarker compositions and methods
|
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
|
AU2014274864B2
(en)
|
2013-06-05 |
2018-10-18 |
Salk Institute For Biological Studies |
Vitamin D receptor agonists to treat diseases involving CXCL12 activity
|
|
CA2920377A1
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
EP3650014B1
(en)
*
|
2013-08-27 |
2021-10-06 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
WO2015143092A1
(en)
|
2014-03-18 |
2015-09-24 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
EP3157921A1
(en)
|
2014-06-23 |
2017-04-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
EP3307778A1
(en)
|
2015-06-12 |
2018-04-18 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
|
ES2907489T3
(es)
*
|
2015-12-14 |
2022-04-25 |
X4 Pharmaceuticals Inc |
Métodos para el tratamiento del cáncer
|
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
ES2935834T3
(es)
|
2015-12-22 |
2023-03-10 |
X4 Pharmaceuticals Inc |
Métodos para tratar enfermedad de inmunodeficiencia
|
|
US20190030023A1
(en)
|
2016-01-22 |
2019-01-31 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
ES3014978T3
(en)
|
2016-04-14 |
2025-04-28 |
Creatv Microtech Inc |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
US20200138804A1
(en)
|
2017-06-21 |
2020-05-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN111465613A
(zh)
|
2017-11-07 |
2020-07-28 |
X4 制药有限公司 |
癌症生物标志物及其使用方法
|
|
US20210009557A1
(en)
|
2017-12-19 |
2021-01-14 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
|
US20210025895A1
(en)
|
2018-04-13 |
2021-01-28 |
X4 Pharmaceuticals, Inc. |
Cancer serum biomarkers and methods of use thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|